Mechanisms of inflammation in premature ovarian insufficiency and advances in therapeutic studies.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms, animal models, and theoretical therapeutic targets without systematic review methodology.
PubMed 41972141 · doi:10.3389/fimmu.2026.1765073
What was done
This narrative review synthesized literature examining the role of chronic inflammation in the pathogenesis of premature ovarian insufficiency (POI). The authors reviewed mechanistic pathways involving cytokine imbalances, autoimmune responses, and ovarian microenvironment alterations across multiple POI animal models (natural aging, chemotherapy-induced, autoimmune, and genetic), and summarized emerging anti-inflammatory therapeutic approaches.
What was found
The abstract reports no numerical values, sample sizes, or quantitative effect estimates. It qualitatively describes mechanisms wherein inflammation accelerates follicular cell apoptosis, follicular atresia, and tissue fibrosis, noting that immunosuppressants and anti-inflammatory interventions have modulated inflammation and improved ovarian function in preclinical models.
Why it matters
It highlights immune dysregulation as a contributor to ovarian failure and frames targeted immunomodulation as a potential therapeutic approach for specific POI patient subsets.
Limits
The paper is a non-systematic narrative review providing no quantitative data. Given the etiological heterogeneity of POI, enhanced inflammatory profiles are not present in all patients, and targeted anti-inflammatory strategies have not been validated in prospective human clinical trials.